Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OM0M
|
|||
| Former ID |
DCL000448
|
|||
| Drug Name |
AVE1625
|
|||
| Synonyms |
Drinabant; 358970-97-5; AVE-1625; AVE1625; UNII-61S98RLL5I; 61S98RLL5I; Drinabant [INN]; SCHEMBL684143; C23H20Cl2F2N2O2S; CHEMBL3545166; CTK8E8263; DTXSID50189455; MolPort-009-019-211; ZINC59299699; 1745AH; RT-011348; 970D975; Methanesulfonamide, N-(1-(bis(4-chlorophenyl)methyl)-3-azetidinyl)-N-(3,5-difluorophenyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Discontinued in Phase 2 | [1] | |
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H20Cl2F2N2O2S
|
|||
| Canonical SMILES |
CS(=O)(=O)N(C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)F)F
|
|||
| InChI |
1S/C23H20Cl2F2N2O2S/c1-32(30,31)29(21-11-19(26)10-20(27)12-21)22-13-28(14-22)23(15-2-6-17(24)7-3-15)16-4-8-18(25)9-5-16/h2-12,22-23H,13-14H2,1H3
|
|||
| InChIKey |
IQQBRKLVEALROM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 358970-97-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020616) | |||
| REF 2 | Pharma & Vaccines. Product Development Pipeline. April 29 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.